What is the role of ceftaroline in the treatment of community-acquired pneumonia (CAP)?

Updated: Oct 28, 2019
  • Author: Fariba M Donovan, MD, PhD; Chief Editor: Thomas E Herchline, MD  more...
  • Print


Ceftaroline fosamil is a parenteral cephalosporin antibacterial that was approved by the FDA in 2010 for the treatment of adults with CAP caused by S pneumoniae, including cases with concurrent bacteremia; S aureus (methicillin-susceptible isolates only); H influenza; K pneumonia; Klebsiella oxytoca; and E coli.

Ceftaroline, the active form of ceftaroline fosamil, has broad-spectrum in vitro activity against common causative gram-positive and gram-negative bacteria, including MRSA. However, there are no clinical data supporting the use of ceftaroline fosamil for MRSA pneumonia. [5]

Ceftaroline fosamil is included in Joint Commission pneumonia core measures as one of the recommended beta-lactam antibiotics for CAP in immunocompetent, non-ICU patients.

Dosing for ceftaroline is as follows:

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!